J B Buse

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi request reprint Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes
    John B Buse
    Diabetes Care Center, University of North Carolina, Chapel Hill, USA
    J Clin Psychiatry 63:37-41. 2002
  2. pmc Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin
    TIL STURMER
    Corresponding author John B Buse
    Diabetes Care 36:3517-25. 2013
  3. pmc Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals
    Alexandra Schneider
    Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Institute of Epidemiology, Neuherberg, Germany
    Part Fibre Toxicol 7:14. 2010
  4. pmc Development and validation of the Diabetes Numeracy Test (DNT)
    Mary Margaret Huizinga
    Division of General Internal Medicine and Public Health, Department of Medicine, Center for Health Services Research, Vanderbilt University Medical Center, Nashville, USA
    BMC Health Serv Res 8:96. 2008
  5. pmc Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience
    John B Buse
    Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Diabetes Technol Ther 13:601-6. 2011
  6. doi request reprint A dead heat: target normal glucose levels in the intensive care unit--but with caution
    J B Buse
    Division of Endocrinology, University of North Carolina School of Medicine, CB 7172, 8027 Burnett Womack Building, Chapel Hill, NC 27599 7172, USA
    Diabetologia 51:909-10. 2008
  7. ncbi request reprint Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods
    John B Buse
    Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7172, USA
    Am J Cardiol 99:21i-33i. 2007
  8. ncbi request reprint A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States
    John B Buse
    Diabetes Care Center and Division of General Medicine, University of North Carolina School of Medicine, 5039 Old Clinic Building, CB 7110, Chapel Hill, NC 27599 7110, USA
    J Clin Epidemiol 56:164-70. 2003
  9. ncbi request reprint Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes
    John B Buse
    University of North Carolina School of Medicine, Chapel Hill, 27599, USA
    Clin Ther 27:1181-95. 2005
  10. ncbi request reprint Are prescribing patterns of antidiabetic medications influenced by fears of litigation?
    John B Buse
    Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7172, USA
    Nat Clin Pract Endocrinol Metab 4:440-1. 2008

Detail Information

Publications53

  1. ncbi request reprint Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes
    John B Buse
    Diabetes Care Center, University of North Carolina, Chapel Hill, USA
    J Clin Psychiatry 63:37-41. 2002
    ....
  2. pmc Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin
    TIL STURMER
    Corresponding author John B Buse
    Diabetes Care 36:3517-25. 2013
    ..To add to the evidence on comparative long-term effects of insulin analog glargine versus human NPH insulin on the risk for cancer...
  3. pmc Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals
    Alexandra Schneider
    Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Institute of Epidemiology, Neuherberg, Germany
    Part Fibre Toxicol 7:14. 2010
    ..This study examined effects of short-term exposures to ambient PM2.5 on markers of systemic inflammation, coagulation, autonomic control of heart rate, and repolarization in 22 adults (mean age: 61 years) with type 2 diabetes...
  4. pmc Development and validation of the Diabetes Numeracy Test (DNT)
    Mary Margaret Huizinga
    Division of General Internal Medicine and Public Health, Department of Medicine, Center for Health Services Research, Vanderbilt University Medical Center, Nashville, USA
    BMC Health Serv Res 8:96. 2008
    ..This paper describes the development and psychometric properties of the Diabetes Numeracy Test (DNT), the first scale to specifically measure numeracy skills used in diabetes...
  5. pmc Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience
    John B Buse
    Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Diabetes Technol Ther 13:601-6. 2011
    ..5% A1C change at 1 year of therapy without incidence of severe hypoglycemia (defined as A1C benefit)...
  6. doi request reprint A dead heat: target normal glucose levels in the intensive care unit--but with caution
    J B Buse
    Division of Endocrinology, University of North Carolina School of Medicine, CB 7172, 8027 Burnett Womack Building, Chapel Hill, NC 27599 7172, USA
    Diabetologia 51:909-10. 2008
  7. ncbi request reprint Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods
    John B Buse
    Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7172, USA
    Am J Cardiol 99:21i-33i. 2007
    ....
  8. ncbi request reprint A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States
    John B Buse
    Diabetes Care Center and Division of General Medicine, University of North Carolina School of Medicine, 5039 Old Clinic Building, CB 7110, Chapel Hill, NC 27599 7110, USA
    J Clin Epidemiol 56:164-70. 2003
    ..An increased risk of developing diabetes compared with the AdvancePCS general patient population was observed during treatment with conventional or atypical antipsychotics...
  9. ncbi request reprint Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes
    John B Buse
    University of North Carolina School of Medicine, Chapel Hill, 27599, USA
    Clin Ther 27:1181-95. 2005
    ..Peroxisome proliferator-activated receptors (PPARs) present a therapeutic target, and simultaneous activation of PPAR-alpha and PPAR-gamma may provide improvements in glycemic control and dyslipidemia in patients with type 2 diabetes...
  10. ncbi request reprint Are prescribing patterns of antidiabetic medications influenced by fears of litigation?
    John B Buse
    Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7172, USA
    Nat Clin Pract Endocrinol Metab 4:440-1. 2008
  11. pmc DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes
    John B Buse
    Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Diabetes Care 32:1007-13. 2009
    ..To compare the ability of two starter insulin regimens to achieve glycemic control in a large, ethnically diverse population with type 2 diabetes...
  12. doi request reprint Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
    John B Buse
    Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Lancet 374:39-47. 2009
    ..We compared the efficacy and safety of liraglutide, a human GLP-1 analogue, with exenatide, an exendin-based GLP-1 receptor agonist...
  13. pmc DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks
    John B Buse
    Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Diabetes Care 33:1255-61. 2010
    ..We now report the safety and efficacy of exenatide QW in 1) patients who continued treatment for an additional 22 weeks (52 weeks total) and 2) patients who switched from exenatide BID to exenatide QW after 30 weeks...
  14. pmc Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents
    John B Buse
    Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Diabetes Care 33:1300-3. 2010
    ..To evaluate efficacy and safety of switching from twice-daily exenatide to once-daily liraglutide or of 40 weeks of continuous liraglutide therapy...
  15. doi request reprint Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial
    John B Buse
    University of North Carolina School of Medicine, Chapel Hill, 27599, USA
    Ann Intern Med 154:103-12. 2011
    ..Insulin replacement in diabetes often requires prandial intervention to reach hemoglobin A₁(c) (HbA₁(c)) targets...
  16. pmc The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine
    John B Buse
    University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Diabetes Care 34:249-55. 2011
    ....
  17. doi request reprint Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials
    John B Buse
    Division of Endocrinology, University of North Carolina School of Medicine, CB 7172, 8027 Burnett Womack Building, Chapel Hill, North Carolina 27599, USA
    J Clin Endocrinol Metab 96:1695-702. 2011
    ..Therapeutic proteins/peptides can produce immunogenic responses that may increase the risk of adverse events or reduce efficacy...
  18. ncbi request reprint Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon
    John B Buse
    Divisions of Endocrinology and General Medicine, Diabetes Care Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7110, USA
    Endocrinol Metab Clin North Am 34:221-35. 2005
    ....
  19. ncbi request reprint Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker
    John B Buse
    Divisions of Endocrinology and of General Medicine and Clinical Epidemiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Diabetes Technol Ther 5:355-63. 2003
    ..The behavior of this analyte is different from all others used in the management of diabetes, creating potential opportunities for its use in clinical practice...
  20. ncbi request reprint Should postprandial glucose be routinely measured and treated to a particular target? No!
    John B Buse
    Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill 27599, USA
    Diabetes Care 26:1615-8. 2003
  21. ncbi request reprint The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes
    J B Buse
    University of North Carolina Diabetes Care Center, Chapel Hill, NC, USA
    Diabetes Obes Metab 6:133-56. 2004
    ....
  22. ncbi request reprint The use of insulin alone and in combination with oral agents in type 2 diabetes
    J B Buse
    Department of Medicine, and Director, Diabetes Care Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599 7172, USA
    Prim Care 26:931-50. 1999
    ..Application of the strategies and principles of insulin therapy in type 2 diabetes should minimize the burden of complications in patients with the disease...
  23. ncbi request reprint The case for a role for postprandial glucose monitoring in diabetes management
    J B Buse
    University of North Carolina School of Medicine, Chapel Hill, NC 27599 7172, USA
    J Fam Pract 47:S29-36. 1998
    ..An important role for postprandial glucose monitoring with therapy aimed at achieving postprandial glucose targets is suggested by teleologic argument, biochemical information, epidemiologic study, and limited clinical trial data...
  24. pmc Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials
    David L Mount
    Wake Forest University School of Medicine, Winston Salem, NC, USA
    Clin Trials 6:416-29. 2009
    ..Comparing findings from separate trials is necessary to choose among treatment options, however differences among study cohorts may impede these comparisons...
  25. ncbi request reprint Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
    John B Buse
    Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Clin Ther 29:139-53. 2007
    ..Some patients were followed up in open-label extensions to provide 'real-world' exenatide clinical experience...
  26. doi request reprint Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP)
    Kathleen M Dungan
    Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University School of Medicine, Columbus, OH, USA
    Diabetes Metab Res Rev 25:558-65. 2009
    ..Islet neogenesis associated protein (INGAP) has beta cell regenerating effects in experimental models...
  27. doi request reprint Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
    Faramarz Ismail-Beigi
    Department of Medicine, Division of Clinical and Molecular Endocrinology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106 4951, USA
    Lancet 376:419-30. 2010
    ..We investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in people with type 2 diabetes...
  28. ncbi request reprint Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
    John B Buse
    Diabetes Care Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Diabetes Care 27:2628-35. 2004
    ..This study evaluated the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy...
  29. ncbi request reprint Treatment of postprandial hyperglycemia in type 2 diabetes
    E A Fasy
    University of North Carolina School of Medicine, Diabetes Care Center, Chapel Hill, NC 27599, USA
    Postgrad Med 110:14-9. 2001
    ..This article discusses the efficacy of some of these agents as monotherapy and in combination with other drugs...
  30. ncbi request reprint 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes
    Kathleen M Dungan
    Division of Endocrinology, University of North Carolina School of Medicine, Durham, NC, USA
    Diabetes Care 29:1214-9. 2006
    ..The objective of this study is to demonstrate the relationship between 1,5-AG and postprandial hyperglycemia, as assessed by the continuous glucose monitoring system (CGMS) in suboptimally controlled patients with diabetes...
  31. ncbi request reprint A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Ronald B Goldberg
    Division of Endocrinology, Metabolism and Diabetes, University of Miami School of Medicine, Miami, Florida, USA
    Diabetes Care 28:1547-54. 2005
    ..This study examines the lipid and glycemic effects of pioglitazone and rosiglitazone...
  32. pmc Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial
    Matthew C Riddle
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon, USA
    Diabetes Care 33:983-90. 2010
    ..As part of ongoing post hoc analyses of potential mechanisms for this finding, we explored whether on-treatment A1C itself had an independent relationship with mortality...
  33. ncbi request reprint Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association
    John B Buse
    University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Diabetes Care 30:162-72. 2007
    ..This statement will attempt to harmonize the recommendations of both organizations where possible but will recognize areas in which AHA and ADA recommendations differ...
  34. ncbi request reprint Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes
    C Noel Bairey Merz
    Preventive Cardiac Center and Women s Health Program, Cedars Sinai Medical Center, Los Angeles, California, USA
    J Am Coll Cardiol 40:1877-81. 2002
    ..Studies were conducted to: 1) assess physicians' attitudes and practices in managing cardiovascular disease (CVD) risks in diabetes; and 2) determine the awareness of CVD risks among diabetic patients...
  35. ncbi request reprint Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial
    Scott M Grundy
    The University of Texas Southwestern Medical Center, Room Y3206, 5323 Harry Hines Blvd, Dallas, TX 75390 9052
    Arch Intern Med 162:1568-76. 2002
    ..We evaluated the efficacy and safety of once-daily extended-release (ER) niacin in patients with diabetic dyslipidemia...
  36. ncbi request reprint Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia
    Mark A Deeg
    Department of Endocrinology and Metabolism, Veterans Affairs Hospital and Indiana University, Indianapolis, Indiana, USA
    Diabetes Care 30:2458-64. 2007
    ..We studied the effects of pioglitazone (PIO) and rosiglitazone (ROSI) treatments on serum lipoprotein particle concentrations and sizes in type 2 diabetic patients with dyslipidemia...
  37. ncbi request reprint Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
    Orville G Kolterman
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    J Clin Endocrinol Metab 88:3082-9. 2003
    ..This robust antidiabetic effect warrants further evaluation of AC2993...
  38. ncbi request reprint Glitazones and heart failure: critical appraisal for the clinician
    John B Buse
    Circulation 108:e57. 2003
  39. ncbi request reprint Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes
    Anne L Peters Harmel
    University of Southern California, Keck School of Medicine, Los Angeles, CA, USA
    Curr Med Res Opin 20:215-23. 2004
    ..This study was undertaken to assess the effect of pioglitazone hydrochloride and rosiglitazone maleate on blood lipid levels and glycemic control when these drugs are used as adjunctive therapy in type 2 diabetes...
  40. ncbi request reprint Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
    David C Goff
    Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1063, USA
    Am J Cardiol 99:4i-20i. 2007
    ..The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial will test hypotheses to address these unanswered questions...
  41. ncbi request reprint A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes
    Kathleen M Dungan
    Ohio State University School of Medicine, Columbus, OH, USA
    Curr Med Res Opin 23:2689-95. 2007
    ..Patients with diabetes often do not reach recommended lipid targets. This may be in part due to the difficulty of obtaining fasting measurements...
  42. ncbi request reprint Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
    David C Klonoff
    Diabetes Research Institute, Mills Peninsula Health Services, San Mateo, CA, USA
    Curr Med Res Opin 24:275-86. 2008
    ..The objective of this study was to evaluate the effects of > or = 3 years exenatide therapy on glycemic control, body weight, cardiometabolic markers, and safety...
  43. doi request reprint Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Stud
    David M Nathan
    Diabetes Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Diabetes Care 31:173-5. 2008
  44. ncbi request reprint Should postprandial glucose be routinely measured and treated to a particular target? Connecting the two sides of the debate
    John B Buse
    Diabetes Care 26:2700-1. 2003
  45. doi request reprint Effects of intensive glucose lowering in type 2 diabetes
    Hertzel C Gerstein
    N Engl J Med 358:2545-59. 2008
    ....
  46. pmc Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change
    Richard W Grant
    General Medicine Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Diabetes Care 28:337-442. 2005
    ..To assess both standard and novel diabetes quality measures in a national sample of U.S. academic medical centers...
  47. pmc Frontline: diabetes--supplementing education and quality improvement in family medicine residency training
    Peter J Carek
    Ann Fam Med 6:88-9. 2008
  48. ncbi request reprint The prevention or delay of type 2 diabetes
    Robert S Sherwin
    Diabetes Care 26:S62-9. 2003
  49. ncbi request reprint Prevention or delay of type 2 diabetes
    Robert S Sherwin
    Diabetes Care 27:S47-54. 2004
  50. ncbi request reprint The insulin resistance syndrome and coronary artery disease
    David M Kendall
    International Diabetes Center, Park Nicollet Clinic, 3800 Park Nicollet Blvd, St Louis Park, MN 55416, USA
    Coron Artery Dis 14:335-48. 2003
    ..A proposed approach to the management of patients with the insulin resistance syndrome is discussed...
  51. ncbi request reprint Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association
    John B Buse
    University of North Carolina, USA
    Circulation 115:114-26. 2007
    ..This statement will attempt to harmonize the recommendations of both organizations where possible but will recognize areas in which AHA and ADA recommendations differ...
  52. ncbi request reprint Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
    David M Nathan
    Diabetes Center, Massachusetts General Hospital, Boston, 02114, USA
    Diabetes Care 29:1963-72. 2006